The DRESS study has shown that safety and efficacy were maintained for up to 3 years upon disease activity-guided dose reduction of TNF inhibitors. However, which patients are ideally suited for de-escalation remains to be investigated.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Rheumatoid arthritis
Inflammation and Regeneration Open Access 07 September 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Smolen, J. S. et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. 2016 update. Ann. Rheum. Dis. 76, 960–977 (2017).
Singh, J. A. et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 68, 1–26 (2016).
Bouman, C. A. et al. Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study — a randomised controlled pragmatic non-inferiority strategy trial. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211169 (2017).
Tanaka, Y., Hirata, S., Saleem, B. & Emery, P. Discontinuation of biologics in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 31, S22–S27 (2013).
Schett, G. et al. Tapering DMARD therapy in rheumatoid arthritis — current evidence and future directions. Ann. Rheum. Dis. 75, 1428–1437 (2016).
van Herwaarden, N. et al. Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350, h1389 (2015).
Nam, J. L. et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann. Rheum. Dis. 73, 75–85 (2014).
Smolen, J. S. et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomized controlled trial. Lancet 381, 918–929 (2013).
Haschka, J. et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann. Rheum. Dis. 75, 45–51 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Y.T. has received consulting fees, speaking fees and/or honoraria from Astellas, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Janssen, Mitsubishi-Tanabe Pharma, Pfizer, Sanofi, UCB and YL Biologics and has received research grants from Abbvie, Astellas, Bristol-Myers Squibb, Chugai Pharma, Daiichi Sankyo, Eisai, Kyowa Hakko Kirin, Mitsubishi-Tanabe, MSD, Ono Pharmaceutical, Pfizer and Takeda.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tanaka, Y. DMARD de-escalation — let the patient guide you. Nat Rev Rheumatol 13, 637–638 (2017). https://doi.org/10.1038/nrrheum.2017.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.128
This article is cited by
-
Rheumatoid arthritis
Inflammation and Regeneration (2020)
-
CP-25, a compound derived from paeoniflorin: research advance on its pharmacological actions and mechanisms in the treatment of inflammation and immune diseases
Acta Pharmacologica Sinica (2020)
